Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation for healthcare conferences, analysts, stockholders, and other audiences.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated corporate presentation for healthcare conferences, analysts, stockholders, and other audiences
- Exhibit 99.1 contains the presentation and may include updated business, clinical, or commercial information
- Investor significance depends on substantive disclosures within the attached presentation
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue guidance $350M–$370M, with Q2 guidance $86M–$88M and ~45% expected year-over-year growth
- Amtagvi commercial infrastructure expanding to >90 authorized treatment centers across multiple markets
- Cash ~$319M as of 3/31/26, with management projecting runway into 2028
- NSCLC program targets potential 2H27 launch, supported by 25.6% ORR and median response duration not reached
- Profitability remains execution-dependent, with 1Q26 gross margin 41% affected by one-time costs and ongoing cost-reduction initiatives
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.